Trial reportPsychopharmacology2010
Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance.
Trial report in Psychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of psychotropic drugs on ocular parameters relevant to traffic safety: A systematic review.Neuroscience and biobehavioral reviews · 2022Pooled it
- The effects of ketamine and risperidone on eye movement control in healthy volunteers.Translational psychiatry · 2013Trial
- Inattention, impulsive action, and subjective response to D-amphetamine.Drug and alcohol dependence · 2013Trial
- Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.Neuroscience · 2013Trial
- Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy.Psychopharmacology · 2012Trial
- Moderate-to-Vigorous Physical Activity and Response Inhibition Predict Balance in Adults with Attention Deficit/Hyperactivity Disorder.Journal of clinical medicine · 2024Article
- Application and progress of advanced eye movement examinations in cognitive impairment.Frontiers in aging neuroscience · 2024Review
- Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.British journal of pharmacology · 2017Review
- Linking ADHD to the Neural Circuitry of Attention.Trends in cognitive sciences · 2017Review
- Baseline-dependent effects of amphetamine on attention are associated with striatal dopamine metabolism.Scientific reports · 2017Article
- Improvement of attention with amphetamine in low- and high-performing rats.Psychopharmacology · 2016Article
- Amphetamine-induced dopamine release and neurocognitive function in treatment-naive adults with ADHD.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- Relating dopaminergic and cholinergic polymorphisms to spatial attention in infancy.Developmental psychology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleBaseline performance has been reported to predict dopamine (DA) effects on working memory, following an inverted-U pattern. This pattern may hold true for other executive functions that are DA-sensitive.
objectivesThe objective of this study is to investigate the effect of D: -amphetamine, an indirect DA agonist, on two other putatively DA-sensitive executive functions, inhibition and motor planning, as a function of baseline performance.
methodsParticipants with no prior stimulant exposure participated in a double-blind crossover study of a single dose of 0.3 mg/kg, p.o. of D: -amphetamine and placebo. Participants were divided into high and low groups, based on their performance on the antisaccade and predictive saccade tasks on the baseline day. Executive functions, mood states, heart rate and blood pressure were assessed before (T0) and after drug administration, at 1.5 (T1), 2.5 (T2) and 3.5 h (T3) post-drug.
resultsAntisaccade errors decreased with D: -amphetamine irrespective of baseline performance (p = 0.025). For antisaccade latency, participants who generated short-latency antisaccades at baseline had longer latencies on D: -amphetamine than placebo, while those with long-latency antisaccades at baseline had shorter latencies on D: -amphetamine than placebo (drug x group, p = 0.04). D: -amphetamine did not affect motor planning. Ratings of mood improved on D: -amphetamine (p < 0.001). Magnitude of D: -amphetamine-induced changes in elation was related to baseline reaction time variability.
conclusionsD: -amphetamine reduced antisaccade error rates in healthy controls, replicating and extending findings with DA agonists in clinical populations. D: -amphetamine had baseline-dependent effects on antisaccade latency, consistent with an inverted-U relationship between performance and DA activity.
Indexed as
Identifiers
20602089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.